top of page

Oral antiviral therapy for COVID-19? update to our management guidelines - Jan 26, 2022

Oral antiviral therapy (nirmatrelvir/ritonavir or Paxlovid) is now available in Quebec for selected patients who are at high risk of progression to severe disease AND identified early (<5days) after onset of symptoms.. Beware drug-drug interactions and limited supply - our latest guidelines offer an approach for outpatient management of COVID-19 for vulnerable high-risk patients. Enjoy!

53 views0 comments

Recent Posts

See All

S.aureus bacteremia

The ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus aureus bacteremia. The diagnostic and antibiotic choice are di

Occupational exposure prophylaxy guidelines

ASP committee developed a post-exposure prophylaxis (HIV, hepB & hepC) guidelines in collaboration with the CVIS team. It is available on our website! Francois Bourdeau ASP MUHC coordinator

Update in COVID guidelines

The ASP committee updated the COVID guidelines. You will find the following change: -Removal of the pre-exposure prophylaxis guidelines since monoclonal antibodies are no longer easly available. -Clar


bottom of page